Safety of Concurrent Radiotherapy and Cabozantinib Use for Treating Patients With Metastatic RCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Real-world Practice Patterns and Safety of Concurrent Radiotherapy and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
Eur Urol Focus 2022 Oct 31;[EPub Ahead of Print], C Loo Gan, J Huang, E Pan, W Xie, AL Schmidt, C Labaki, L Meza, G Bouchard, H Li, F Jackson-Spence, C Sánchez-Ruiz, T Powles, SA Kumar, N Weise, WA Hall, BS Rose, B Beuselinck, C Suarez, SK Pal, TK Choueiri, DYC Heng, RR McKayFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.